Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells - A completed study overview

Biochemical Society Transactions

Volumn 44, Issue 3, 2016, Pages 951-959

  Lamers, Cor H J ^a   Klaver, Yarne ^a   Gratama, Jan W ^a   Sleijfer, Stefan ^a   Debets, Reno ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Adoptive t cell therapy; Carboxy anhydrase IX; Chimeric antigen receptor; Clinical study; Immune monitoring; On target toxicity; Renal cell cancer

Indexed keywords

CARBONATE DEHYDRATASE; CHIMERIC ANTIGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GIRENTUXIMAB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIVER ENZYME; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BB; T LYMPHOCYTE ANTIBODY; CHIMERIC PROTEIN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANTIBODY BLOOD LEVEL; ARTICLE; BILE DUCT; CANCER SURVIVAL; CELL ENGINEERING; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; INTERFERON PRODUCTION; KIDNEY METASTASIS; LIVER BIOPSY; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; BLOOD; CARCINOMA, RENAL CELL; CLINICAL TRIAL; IMMUNOLOGY; KIDNEY NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SECONDARY; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; KIDNEY NEOPLASMS; MUTANT CHIMERIC PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 85009814504     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20160037     Document Type: Article

References (65)

1. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci. Transl. Med. 3, 95ra73 PubMed.
2. Robbins, P.F., Morgan, R.A., Feldman, S.A., Yang, J.C., Sherry, R.M., Dudley, M.E., Wunderlich, J.R., Nahvi, A.V., Helman, L.J., Mackall, C.L. et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 CrossRef PubMed.
3. Lamers, C.H., Sleijfer, S., Vulto, A.G., Kruit, W.H., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G. and Oosterwijk, E. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22 CrossRef PubMed.
4. Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X., James, S.E., Raubitschek, A., Forman, S. et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271 CrossRef PubMed.
5. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P. et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 CrossRef PubMed.
6. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R. et al. (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 CrossRef PubMed.
7. Parkhurst, M.R., Yang, J.C., Langan, R.C., Dudley, M.E., Nathan, D.A., Feldman, S.A., Davis, J.L., Morgan, R.A., Merino, M.J., Sherry, R.M. et al. (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626 CrossRef PubMed.
8. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. and Rosenberg, S.A. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851 CrossRef PubMed.
9. Janetzki, S., Panageas, K.S., Ben-Porat, L., Boyer, J., Britten, C.M., Clay, T.M., Kalos, M., Maecker, H.T., Romero, P., Yuan, J. et al. (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57, 303-315 CrossRef PubMed.
10. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M. et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 CrossRef PubMed.
11. Kunert, A., Straetemans, T., Govers, C., Lamers, C., Mathijssen, R., Sleijfer, S. and Debets, R. (2013) TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol. 4, 363 CrossRef PubMed.
12. Weijtens, M.E.M., Willemsen, R.A., Valerio, D., Stam, K. and Bolhuis, R.L.H. (1996) Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol. 157, 836-843 PubMed.
13. Weijtens, M.E., Willemsen, R.A., Valerio, D., Stam, K. and Bolhuis, R.L. (1996) Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol. 157, 836-843 PubMed.
14. Kuster, H., Thompson, H. and Kinet, J.P. (1990) Characterization and expression of the gene for the human Fc receptor gamma subunit. Definition of a new gene family. J. Biol. Chem. 265, 6448-6452.
15. Oosterwijk, E., Ruiter, D.J., Hoedemaeker, P.J., Pauwels, E.K., Jonas, U., Zwartendijk, J. and Warnaar, S.O. (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494 CrossRef PubMed.
16. Lamers, C.H., Willemsen, R.A., Luider, B.A., Debets, R. and Bolhuis, R.L. (2002) Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 9, 613-623 CrossRef PubMed.
17. Lamers, C., van Elzakker, P., Langeveld, S., Sleijfer, S. and Gratama, J. (2006) Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy 8, 542-553 CrossRef PubMed.
18. Lamers, C.H., Willemsen, R.A., van Elzakker, P., van Krimpen, B.A., Gratama, J.W. and Debets, R. (2006) Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 13, 503-509 CrossRef PubMed.
19. Klaver, Y., Steenbergen van, S.C.L., Sleijfer, S., Debets, R. and Lamers, C.H.J. (2016) Phenotypic and functional characterization of therapeutic CAR T cells to treat renal cell cancer patients, (personal communication).
20. Gattinoni, L., Powell Jr, D.J., Rosenberg, S.A. and Restifo, N.P. (2006) Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393 CrossRef PubMed.
21. Klaver, Y., Steenbergen van, S.C.L., Sleijfer, S., Debets, R. and Lamers, C.H.J. (2016), Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells, (personal communication).
22. Lamers, C.H., Gratama, J.W., Pouw, N.M., Langeveld, S.C., Krimpen, B.A., Kraan, J., Stoter, G. and Debets, R. (2005) Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression. Hum. Gene Ther. 16, 1452-1462 CrossRef PubMed.
23. Burns, W.R., Zheng, Z., Rosenberg, S.A. and Morgan, R.A. (2009) Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114, 2888-2899 CrossRef PubMed.
24. Lamers, C.H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R. et al. (2013) Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904-912 CrossRef PubMed.
25. Brouwers, A.H., Mulders, P.F., de Mulder, P.H., van den Broek, W.J., Buijs, W.C., Mala, C., Joosten, F.B., Oosterwijk, E., Boerman, O.C., Corstens, F.H. et al. (2005) Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J. Clin. Oncol. 23, 6540-6548 CrossRef PubMed.
26. Steffens, M.G., Boerman, O.C., Oyen, W.J., Kniest, P.H., Witjes, J.A., Oosterhof, G.O., van Leenders, G.J., Debruyne, F.M., Corstens, F.H. and Oosterwijk, E. (1999) Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 59, 1615-1619 PubMed.
27. Steffens, M.G., Oosterwijk-Wakka, J.C., Zegwaart-Hagemeier, N.E., Boerman, O.C., Debruyne, F.M., Corstens, F.H. and Oosterwijk, E. (1999) Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 19, 1197-1200 PubMed.
28. Lamers, C.H., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R. and Gratama, J.W. (2011) Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82 CrossRef PubMed.
29. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L. et al. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6015 CrossRef PubMed.
30. Park, J.R., Digiusto, D.L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H.B., Bautista, C., Chang, W.C., Ostberg, J.R. et al. (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825-833 PubMed.
31. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rossig, C., Russell, H.V., Diouf, O., Liu, E. et al. (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056 CrossRef PubMed.
32. Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z. et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826 CrossRef PubMed.
33. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O. et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 CrossRef PubMed.
34. Ritchie, D.S., Neeson, P.J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D.M., Honemann, D. et al. (2013) Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21, 2122-2129 CrossRef PubMed.
35. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N. et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 CrossRef PubMed.
36. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F. et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 CrossRef PubMed.
37. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M. et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 PubMed.
38. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England J. Med. 365, 725-733 CrossRef.
39. Lamers, C.H., Langeveld, S.C., Groot-van Ruijven, C.M., Debets, R., Sleijfer, S. and Gratama, J.W. (2007) Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol. Immunother. 56, 1875-1883 CrossRef PubMed.
40. Bleumer, I., Knuth, A., Oosterwijk, E., Hofmann, R., Varga, Z., Lamers, C., Kruit, W., Melchior, S., Mala, C., Ullrich, S. et al. (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90, 985-990 CrossRef PubMed.
41. Lamers, C.H. and Debets, R. (2013) Genetically modified T lymphocytes: more than just direct effectors. Immunotherapy 5, 691-694 CrossRef PubMed.
42. Davis, J.L., Theoret, M.R., Zheng, Z., Lamers, C.H., Rosenberg, S.A. and Morgan, R.A. (2010) Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 16, 5852-5861 CrossRef PubMed.
43. Cheever, M.A., Allison, J.P., Ferris, A.S., Finn, O.J., Hastings, B.M., Hecht, T.T., Mellman, I., Prindiville, S.A., Viner, J.L., Weiner, L.M. et al. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323-5337 CrossRef PubMed.
44. Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.C., Dudley, M.E., Wunderlich, J.R., Somerville, R.P., Hogan, K., Hinrichs, C.S. et al. (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 CrossRef PubMed.
45. Lucas, S., De Plaen, E. and Boon, T. (2000) MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 87, 55-60 CrossRef PubMed.
46. Straetemans, T., van Brakel, M., van Steenbergen, S., Broertjes, M., Drexhage, J., Hegmans, J., Lambrecht, B.N., Lamers, C., Bruggen, P.D., Coulie, P.G. et al. (2012) TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin. Dev. Immunol. 2012, 586314 CrossRef PubMed.
47. Gnjatic, S., Nishikawa, H., Jungbluth, A.A., Gure, A.O., Ritter, G., Jager, E., Knuth, A., Chen, Y.T. and Old, L.J. (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95, 1-30 CrossRef PubMed.
48. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F. et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 CrossRef PubMed.
49. Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M. et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151 CrossRef PubMed.
50. Linette, G.P., Stadtmauer, E.A., Maus, M.V., Rapoport, A.P., Levine, B.L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P.J. et al. (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863-871 CrossRef PubMed.
51. Cameron, B.J., Gerry, A.B., Dukes, J., Harper, J.V., Kannan, V., Bianchi, F.C., Grand, F., Brewer, J.E., Gupta, M., Plesa, G. et al. (2013) Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra03.
52. Klaver, Y., Kunert, A., Sleijfer, S., Debets, R. and Lamers, C.H. (2015) Adoptive T-cell therapy: a need for standard immune monitoring. Immunotherapy 7, 513-533 CrossRef PubMed.
53. Anurathapan, U., Leen, A.M., Brenner, M.K. and Vera, J.F. (2014) Engineered T cells for cancer treatment. Cytotherapy 16, 713-733 CrossRef PubMed.
54. Chmielewski, M. and Abken, H. (2012) CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol. Immunother. 61, 1269-1277 CrossRef PubMed.
55. Pegram, H.J., Park, J.H. and Brentjens, R.J. (2014) CD28z CARs and armored CARs. Cancer J. 20, 127-133 CrossRef PubMed.
56. Pegram, H.J., Purdon, T.J., van Leeuwen, D.G., Curran, K.J., Giralt, S.A., Barker, J.N. and Brentjens, R.J. (2015) IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 29, 415-422.
57. Klebanoff, C.A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A.R., Finkelstein, S.E., Palmer, D.C., Antony, P.A., Hwang, S.T., Rosenberg, S.A. et al. (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U.S.A. 102, 9571-9576 CrossRef PubMed.
58. Hinrichs, C.S., Borman, Z.A., Gattinoni, L., Yu, Z., Burns, W.R., Huang, J., Klebanoff, C.A., Johnson, L.A., Kerkar, S.P., Yang, S. et al. (2011) Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808-814 CrossRef PubMed.
59. Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J. et al. (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169-180 CrossRef PubMed.
60. Gomez-Eerland, R., Nuijen, B., Heemskerk, B., van Rooij, N., van den Berg, J.H., Beijnen, J.H., Uckert, W., Kvistborg, P., Schumacher, T.N., Haanen, J.B. et al. (2014) Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. Hum. Gene Ther. Methods 25, 277-287 CrossRef PubMed.
61. Lamers, C.H., van Steenbergen-Langeveld, S., van Brakel, M., Groot-van Ruijven, C.M., van Elzakker, P.M., van Krimpen, B., Sleijfer, S. and Debets, R. (2014) T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. Hum. Gene Ther. Methods 25, 345-357 CrossRef PubMed.
62. Pouw, N., Treffers-Westerlaken, E., Kraan, J., Wittink, F., ten Hagen, T., Verweij, J. and Debets, R. (2010) Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 59, 921-931 CrossRef PubMed.
63. Pouw, N., Treffers-Westerlaken, E., Mondino, A., Lamers, C. and Debets, R. (2010) TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol. Immunol. 47, 1411-1420 CrossRef PubMed.
64. Casati, A., Varghaei-Nahvi, A., Feldman, S.A., Assenmacher, M., Rosenberg, S.A., Dudley, M.E. and Scheffold, A. (2013) Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol. Immunother. 62, 1563-1573 CrossRef PubMed.
65. Govers, C., Sebestyen, Z., Roszik, J., van Brakel, M., Berrevoets, C., Szoor, A., Panoutsopoulou, K., Broertjes, M., Van, T., Vereb, G. et al. (2014) TCRs genetically linked to CD28 and CD3epsilon do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. J. Immunol. 193, 5315-5326 CrossRef PubMed.